Literature DB >> 23983425

Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Jia-Yuan Peng1, Zhong-Nan Li, Yu Wang.   

Abstract

Local recurrence (LR) has an adverse impact on rectal cancer treatment. Neoadjuvant chemoradiotherapy (nCRT) is increasingly administered to patients with progressive cancers to improve the prognosis. However, LR still remains a problem and its pattern can alter. Correspondingly, new risk factors have emerged in the context of nCRT in addition to the traditional risk factors in patients receiving non-neoadjuvant therapies. These risk factors are decisive when reviewing treatment options. This review aims to elucidate the distinctive risk factors related to LR of rectal cancers in patients receiving nCRT and to clarify their clinical significance. A search was conducted on PubMed to identify original studies investigating patients with rectal cancer receiving nCRT. Outcomes of interest, especially potential risk factors for LR in patients with nCRT, were then analyzed. The clinical importance of these risk factors is discussed. Remnant cancer cells, lymph-nodes and tumor response were found to be major risk factors. Remnant cancer cells decide the status of resection margins. Local excision following nCRT is promising in ypT0-1N0M0 cases. Dissection of lateral lymph nodes should be considered in advanced low-lying cancers. Although better tumor response resulted in a relatively lower recurrence rate, the evidence available is insufficient to justify a non-operative approach in clinical complete responders to nCRT. LR cannot be totally avoided by current multidisciplinary approaches. The related risk factors resulting from nCRT should be considered when making decisions regarding treatment selection.

Entities:  

Keywords:  Local recurrence; Neoadjuvant chemoradiotherapy; Rectal cancer

Mesh:

Year:  2013        PMID: 23983425      PMCID: PMC3752556          DOI: 10.3748/wjg.v19.i32.5227

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  101 in total

Review 1.  Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  B Glimelius; J Oliveira
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

2.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.

Authors:  Y Francois; C J Nemoz; J Baulieux; J Vignal; J P Grandjean; C Partensky; J C Souquet; P Adeleine; J P Gerard
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

3.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

4.  The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.

Authors:  J Lindebjerg; K-L G Spindler; J Ploen; A Jakobsen
Journal:  Colorectal Dis       Date:  2008-06-20       Impact factor: 3.788

5.  [Incidence and prognostic significance of mesorectal extranodal tumor deposits in patients with rectal carcinoma following neoadjuvant therapy].

Authors:  D Umlaufová; P Skapa; J Hoch; J Prausová
Journal:  Rozhl Chir       Date:  2009-06

6.  The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer.

Authors:  Marcel den Dulk; Hein Putter; Laurence Collette; Corrie A M Marijnen; Joakim Folkesson; Jean-Francois Bosset; Claus Rödel; Krzysztof Bujko; Lars Påhlman; Cornelis J H van de Velde
Journal:  Eur J Cancer       Date:  2009-01-06       Impact factor: 9.162

7.  Local recurrence in rectal cancer can be predicted by histopathological factors.

Authors:  R C Dresen; E E M Peters; H J T Rutten; G A P Nieuwenhuijzen; T B J Demeyere; A J C van den Brule; A G H Kessels; R G H Beets-Tan; J H J M van Krieken; I D Nagtegaal
Journal:  Eur J Surg Oncol       Date:  2009-04-11       Impact factor: 4.424

8.  Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment.

Authors:  Miranda Kusters; Fabian A Holman; Hendrik Martijn; Grard A Nieuwenhuijzen; Geert-Jan Creemers; Alette W Daniels-Gooszen; Hetty A van den Berg; Adriaan J van den Brule; Cornelis J H van de Velde; Harm J T Rutten
Journal:  Radiother Oncol       Date:  2009-03-30       Impact factor: 6.280

9.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

10.  Patterns of local recurrence in rectal cancer: a single-center experience.

Authors:  M Kusters; C J H van de Velde; R G H Beets-Tan; T Akasu; S Fujita; S Fujida; S Yamamoto; Y Moriya
Journal:  Ann Surg Oncol       Date:  2008-11-18       Impact factor: 5.344

View more
  7 in total

1.  Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system.

Authors:  Antonio Manenti; Luca Roncati; Massimiliano Salati; Emilio Simonini; Maurizio Zizzo; Alberto Farinetti
Journal:  J Gastrointest Oncol       Date:  2017-02

2.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

3.  Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.

Authors:  Teresa Gómez Del Pulgar; Arancha Cebrián; Maria Jesús Fernández-Aceñero; Aurea Borrero-Palacios; Laura Del Puerto-Nevado; Javier Martínez-Useros; Juan Pablo Marín-Arango; Cristina Caramés; Ricardo Vega-Bravo; María Rodríguez-Remírez; Marlid Cruz-Ramos; Félix Manzarbeitia; Jesús García-Foncillas
Journal:  J Cell Mol Med       Date:  2016-05-12       Impact factor: 5.310

4.  Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision.

Authors:  Jieyi Zhao; Huamin Zhao; Tingting Jia; Shiru Yang; Xiaoyu Wang
Journal:  Cancer Manag Res       Date:  2022-09-29       Impact factor: 3.602

5.  Association between irrigation fluids, washout volumes and risk of local recurrence of anterior resection for rectal cancer: a meta-analysis of 427 cases and 492 controls.

Authors:  Can Zhou; Yu Ren; Juan Li; Ke Wang; Jianjun He; Wuke Chen; Peijun Liu
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

6.  Factors predicting recurrence after curative resection for rectal cancer: a 16-year study.

Authors:  Waad Farhat; Mohamed Azzaza; Abdelkader Mizouni; Houssem Ammar; Mahdi Ben Ltaifa; Sami Lagha; Mohamed Kahloul; Rahul Gupta; Mohamed Ben Mabrouk; Ali Ben Ali
Journal:  World J Surg Oncol       Date:  2019-10-28       Impact factor: 2.754

Review 7.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.